ASAdam C. Salisbury

Adam C. Salisbury

*This is an algorithmically generated author record based on publicly available information.

Adam C. Salisbury has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Restenosis Pattern on the Safety and Efficacy of Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis

    by Dany Jacob, Adam Salisbury, J. Aaron Grantham, Richard Shlofmitz, Jeffrey Moses, William Bachinsky, Suhail Dohad, Steven Rudick, Robert Stoler, Brian K. Jefferson, et al.

  • Optimal timing of staged percutaneous coronary intervention after subintimal tracking and re‐entry: Rationale and design of the subintimal tracking and re‐entry with deferred stenting study

    by Taishi Hirai, Kathleen Kearney, Lorenzo Azzalini, Adam C. Salisbury, Nancy Stone, Kensey L. Gosch, Ashish Pershad, William Nicholson, William Lombardi, R. Michael Wyman, et al.

    Background: Ten to fifteen percent of chronic total occlusion (CTO) percutaneous coronary interventions (PCIs) are unsuccessful in contemporary practice. Subintimal tracking and re‐entry (STAR) (one form of “investment procedure”) with staged reattempt and stenting may further increase the ultimate success and safety of CTO as a bailout strategy. The optimal timing for staged stenting after STAR is unknown.Methods and Results: We designed a six‐center, prospective randomized trial with a planned enrollment of 150 patients where STAR is utilized in case of impending failure. The primary aim is to evaluate the optimal timing of the staged PCI after STAR by randomizing the timing to earlier (5–7 weeks) versus later (12–14 weeks) staged PCI. The primary endpoint of the study is the technical success rate of the staged procedure. The secondary endpoints include: (1) the rate of thrombolysis in myocardial infarction 3 flow at the start of staged intervention, (2) rate of partial technical and procedural success of the staged procedure, (3) rate of in‐hospital and 12‐month major cardiac and cerebrovascular adverse events, and (4) change in patient‐reported quality at 30 days, 6 months, and 12 months assessed by Seattle Angina Questionnaire.Conclusion: This study will ascertain the optimal timing of staged stenting after bail‐out STAR approach in contemporary CTO PCI (ClinicalTrials.gov NCT05089864).


  • Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study

    by Taishi Hirai, J. Aaron Grantham, David E. Kandzari, William Ballard, W. Morris Brown, Keith B. Allen, Ajay J. Kirtane, Michael Argenziano, Robert W. Yeh, Kamal Khabbaz, et al.

    Background: Indications and outcomes for percutaneous ventricular assist device (pVAD) use in surgically ineligible patients undergoing percutaneous coronary intervention (PCI) remain poorly characterized.Aims: We sought to describe the use and timing of pVAD and outcome in surgically ineligible patients.Methods: Among 726 patients enrolled in the prospective OPTIMUM study, clinical and health status outcomes were assessed in patients who underwent pVAD‐assisted PCI and those without pVAD.Results: Compared with patients not receiving pVAD (N = 579), those treated with pVAD (N = 142) more likely had heart failure, lower left ventricular ejection fraction (30.7 ± 13.6 vs. 45.9 ± 15.5, p < 0.01), and higher STS 30‐day predicted mortality (4.2 [2.1−8.0] vs. 3.3 [1.7−6.6], p = 0.01) and SYNTAX scores (36.1 ± 12.2, vs. 31.5 ± 12.1, p < 0.01). While the pVAD group had higher in‐hospital (5.6% vs. 2.2%, p = 0.046), 30‐day (9.0% vs. 4.0%, p = 0.01) and 6‐month (20.4% vs. 11.7%, p < 0.01) mortality compared to patients without pVAD, this difference appeared to be largely driven by significantly higher mortality among the 20 (14%) patients with unplanned pVAD use (30% in‐hospital mortality with unplanned PVAD vs. 1.6% with planned, p < 0.01; 30‐day mortality, 38.1% vs. 4.5%, p < 0.01). The degree of 6‐month health status improvement among survivors was similar between groups.Conclusion: Surgically ineligible patients with pVAD‐assisted PCI had more complex baseline characteristics compared with those without pVAD. Higher mortality in the pVAD group appeared to be driven by very poor outcomes by patients with unplanned, rescue pVAD.


  • Open Access

    Hospital-Level Variability in Use of Intracoronary Imaging for Percutaneous Coronary Intervention in the United States

    by Ali O. Malik, John T. Saxon, John A. Spertus, Adam Salisbury, James A. Grantham, Kevin Kennedy, Chetan P. Huded


  • Outcomes of Medical Therapy Plus PCI for Multivessel or Left Main CAD Ineligible for Surgery

    by Adam C. Salisbury, J. Aaron Grantham, W. Morris Brown, William L. Ballard, Keith B. Allen, Ajay J. Kirtane, Michael Argenziano, Robert W. Yeh, Kamal Khabbaz, John Lasala, et al.


  • Health Status Outcomes in Older Adults Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention

    by Dan D. Nguyen, Kensey L. Gosch, Rayan El‐Zein, Paul S. Chan, William L. Lombardi, Dimitri Karmpaliotis, John A. Spertus, R. Michael Wyman, William J. Nicholson, Jeffrey W. Moses, et al.

    Background: Although chronic total occlusions (CTOs) are common in older adults, they are less likely to be offered CTO percutaneous coronary intervention for angina relief than younger adults. The health status impact of CTO percutaneous coronary intervention in adults aged ≥75 years has not been studied. We sought to compare technical success rates and angina‐related health status outcomes at 12 months between adults aged ≥75 and P =0.02]) and numerically higher rates of in‐hospital major adverse cardiovascular events (9.1% versus 5.9%, P =0.10). There was no difference in Seattle Angina Questionnaire Summary Score at 12 months between adults aged ≥75 and P =0.44]). Conclusions: Despite modestly lower success rates and higher complication rates, adults aged ≥75 years experienced angina‐related health status benefits after CTO‐percutaneous coronary intervention that were similar in magnitude to adults aged <75 years. CTO percutaneous coronary intervention should not be withheld based on age alone in otherwise appropriate candidates.


  • Validation of the new PROGRESS‐CTO complication risk scores in the OPEN‐CTO registry

    by Lorenzo Azzalini, Taishi Hirai, Adam Salisbury, Kensey Gosch, James Sapontis, William J. Nicholson, Dimitri Karmpaliotis, Jeffrey W. Moses, Kathleen E. Kearney, William L. Lombardi, et al.

    Background: Risk stratification before chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is important to inform procedural planning as well as patients and their families. We sought to externally validate the PROGRESS‐CTO complication risk scores in the OPEN‐CTO registry.Methods: OPEN‐CTO is a prospective registry of 1000 consecutive CTO PCIs performed at 12 experienced US centers using the hybrid algorithm. Endpoints of interest were in‐hospital all‐cause mortality, need for pericardiocentesis, acute myocardial infarction (MI), and major adverse cardiovascular events (MACE) (a composite of all‐cause mortality, stroke, periprocedural MI, urgent repeat revascularization, and tamponade requiring pericardiocentesis). Model discrimination was assessed with the area under the curve (AUC) method, and calibration with the observed‐versus‐predicted probability method.Results: Mean age was 65.4 ± 10.3 year, and 36.5% of patients had prior coronary artery bypass graft. Overall, 41 patients (4.1%) suffered MACE, 9 (0.9%) mortality, 26 (2.6%) acute MI, and 11 (1.1%) required pericardiocentesis. Technical success was achieved in 86.3%. Patients who experienced MACE had higher anatomic complexity, and more often required antegrade dissection/reentry and the retrograde approach. Increasing PROGRESS‐CTO MACE scores were associated with increasing MACE rates: 0.5% (score 0−1), 2.4% (score 2), 3.7% (score 3), 4.5% (score 4), 7.8% (score 5), 13.0% (score 6−7). The AUC were as follows: MACE 0.72 (95% confidence interval [CI]: 0.66−0.78), mortality 0.79 (95% CI: 0.66−0.95), pericardiocentesis 0.71 (95% CI: 0.60−0.82), and acute MI 0.57 (95% CI: 0.49−0.66). Calibration was adequate for MACE and mortality, while the models underestimated the risk of pericardiocentesis and acute MI.Conclusions: In a large external cohort of patients treated with the hybrid algorithm by experienced CTO operators, the PROGRESS‐CTO MACE, mortality, and pericardiocentesis risk scores showed good discrimination, while the acute MI score had inferior performance.


  • The Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease (OPTIMUM) Registry: Rationale and Design

    by Adam C. Salisbury, Ajay J. Kirtane, Ziad A. Ali, J. Aaron Grantham, William L. Lombardi, Robert W. Yeh, Philippe Genereux, Keith B. Allen, W. Morris Brown, Karen Nugent, et al.


  • Development and validation of a predictive model for bleeding after peripheral vascular intervention: A report from the National Cardiovascular Data Registry Peripheral Vascular Interventions Registry

    by Adam C. Salisbury, David M. Safley, Kevin F. Kennedy, Bhaskar Bhardwaj, Herbert D. Aronow, William Schuyler Jones, Dmitriy N. Feldman, Eric Secemsky, Thomas T. Tsai, Robert R. Attaran, et al.

    Objectives: To develop a model to predict risk of in‐hospital bleeding following endovascular peripheral vascular intervention.Background: Peri‐procedural bleeding is a common, potentially preventable complication of catheter‐based peripheral vascular procedures and is associated with increased mortality. We used the National Cardiovascular Data Registry (NCDR) Peripheral Vascular Interventions (PVI) Registry to develop a novel risk‐prediction model to identify patients who may derive the greatest benefit from application of strategies to prevent bleeding.Methods: We examined all patients undergoing lower extremity PVI at 76 NCDR PVI hospitals from 2014 to 2017. Patients with acute limb ischemia (n = 1600) were excluded. Major bleeding was defined as overt bleeding with a hemoglobin (Hb) drop of ≥ 3 g/dl, any Hb decline of ≥ 4 g/dl, or a blood transfusion in patients with pre‐procedure Hb ≥ 8 g/dl. Hierarchical multivariable logistic regression was used to develop a risk model to predict major bleeding. Model validation was performed using 1000 bootstrapped replicates of the population after sampling with replacement.Results: Among 25,382 eligible patients, 1017 (4.0%) developed major bleeding. Predictors of bleeding included age, female sex, critical limb ischemia, non‐femoral access, prior heart failure, and pre‐procedure hemoglobin. The model demonstrated good discrimination (optimism corrected c‐statistic = 0.67), calibration (corrected slope = 0.98, intercept of −0.04) and range of predicted risk (1%–18%).Conclusions: Post‐procedural PVI bleeding risk can be predicted based upon pre‐ and peri‐procedural patient characteristics. Further studies are needed to determine whether this model can be utilized to improve procedural safety through developing and targeting bleeding avoidance strategies.


  • Development and validation of a prediction model for angiographic perforation during chronic total occlusion percutaneous coronary intervention: OPEN‐CLEAN perforation score

    by Taishi Hirai, James Aaron Grantham, James Sapontis, William J. Nicholson, William Lombardi, Dimitri Karmpaliotis, Jeffrey Moses, Karen Nugent, Kensey L. Gosch, Adam C. Salisbury, et al.

    Background: Perforation is the most frequent complication of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) and is associated with adverse events including mortality.Methods: Among 1,000 consecutive patients enrolled in 12 center prospective CTO PCI study (OPEN CTO), all perforations were reviewed by the angiographic core‐lab. Eighty‐nine patients (8.9%) with angiographic perforation were compared to 911 patients without perforation. We sought to describe the clinical and angiographic predictors of angiographic perforation during CTO PCI and develop a risk prediction model.Results: Among eight clinically important candidate variables, independent risk factors for perforation included prior CABG (OR 2.0 [95% CI, 1.2–3.3], p < .01), occlusion length (OR 1.2 per 10 mm increase [95% CI, 1.1–1.3], p < .01), ejection fraction (OR 1.2 per 10% decrease [95% CI, 1.1–1.5], p < .01), age (OR 1.3 per 5 year increase [95%CI, 1.1–1.5], p < .01), and heavy calcification (OR 1.7 [95% CI, 1.0–2.7], p = .04). Three other potential candidate variables, glomerular filtration rate, proximal cap ambiguity, and target vessel, were not independently associated with perforation. The model was internally validated using bootstrapping methods. From the full model, a simplified perforation prediction score (OPEN‐CLEAN score: CABG, Length [occlusion], EF < 50%, Age, CalcificatioN) was developed, which discriminated the risk of angiographic perforation well (c‐statistics = 0.75) and demonstrated good calibration.Conclusion: This simple 5‐variable prediction score may help CTO operators to risk‐stratify patients for angiographic perforation using variables available prior to CTO PCI procedures.